Invea Therapeutics is a pre-clinical, pre-revenue biotech developing oral, small-molecule drugs for immune-mediated inflammatory diseases (IMIDs), including skin conditions, joint diseases, gastrointestinal diseases, respiratory conditions, and autoimmune neurological diseases. Invea's core argument is that current IMID treatments — primarily injectable biologics and broad immunosuppressants — carry safety risks, inconvenient dosing, high costs, and incomplete responses, and that targeted oral small molecules can address these shortcomings. Invea has two product candidates. The lead asset, INVA8001, is an oral chymase inhibitor originally developed by Daiichi Sankyo and in-licensed by Invea in 2021. INVA8001 is designed to disrupt a feedback loop that drives mast cell proliferation. Daiichi Sankyo previously ran Phase 1 and Phase 2 trials for atopic dermatitis, which failed to meet primary endpoints; Invea believes those trials used sub-therapeutic doses and plans to run its own Phase 2a trial in chronic inducible urticaria in the EU, targeting CTA submission in H2 2026. The second candidate, INVA8003, is an AI-designed oral inhibitor of ASC, a protein involved in inflammasome assembly, and is in preclinical development with IND-enabling studies planned for 2026. Invea uses the AlphaMeld AI/ML drug discovery platform, licensed non-exclusively from its parent company, InveniAI. Invea has no approved products, no revenue, and only ~$0.3M in cash as of September 2025, and is conducting an IPO to fund its pipeline.